EAN 2022: Fremanezumab Cuts Monthly Migraine Days by Half in Real-World Practice
Benefits seen in first six months of real-world treatment also include improvements in migraine-related disability
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.